Tetraphase Pharmaceuticals was established in 2006 to advance and commercialize breakthrough synthetic chemistry developed by world-leading organic chemist Professor Andrew G. Myers, Ph.D., Chair, Department of Chemical Biology at Harvard University. This ground-breaking and transformational advance in chemistry, the Myers process, provides the company with a broad-range of commercial opportunities across a number of significant disease categories. The Company’s initial focus is on the discovery and development of novel antibiotics to treat drug-resistant infections. This enabling technology also provides meaningful opportunities in inflammation and cancer. Flagship General Partner Doug Cole is a Director.

www.tphase.com